STOCK TITAN

Co-Diagnostics (CODX) S-3 Filings

CODX NASDAQ

Here are the S-3 shelf registrations from Co-Diagnostics, Inc. (CODX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.

Rhea-AI Summary

Co-Diagnostics, Inc.'s registration statement covers up to 39,594,495 common shares for resale by J.J. Astor & Co. after effectiveness. Co-Diagnostics receives no proceeds from these resales; Astor receives the net proceeds. The shares include stock issued or issuable on conversion of the Notes, 600,000 commitment shares and applicable make-whole shares. The registered amount equals 200% of the sum of maximum conversion shares at the floor price, commitment shares and applicable make-whole shares, assuming the additional loan is fully funded.

Under an October 9, 2026 loan agreement, Astor initially funded $2.1 million; Co-Diagnostics issued a senior secured convertible note with $2.835 million original principal and received approximately $2.016 million net before other transaction expenses. Subject to the agreement's conditions, the company may borrow another $1.0 million beginning 60 days after the agreement date and issue a $1.35 million original-principal note. The Notes are repaid in 30 weekly installments, secured by liens on substantially all company and subsidiary assets, and require a $250,000 minimum cash balance while outstanding. Co-Diagnostics had 9,491,892 shares outstanding as of October 31, 2026.

Rhea-AI Summary

Co-Diagnostics, Inc. (CODX) is registering the resale of up to 3,404,724 shares of common stock for selling stockholders. These shares are issuable upon exercise of “New Warrants” issued under a July 30, 2026 Inducement Letter. CODX will not receive proceeds from the selling stockholders’ resales.

If all New Warrants are exercised for cash at $1.56 per share, CODX could receive up to approximately $5.31 million, planned for working capital and general corporate purposes; the warrants are also exercisable on a cashless basis, in which case the company would receive no cash. Common shares outstanding were 6,981,319 as of August 20, 2026, or 10,386,043 assuming full exercise of the New Warrants.

CODX develops and sells PCR-based molecular diagnostics, including tests for COVID‑19 and other infectious diseases, and is pursuing U.S. FDA clearance for its Co-Dx PCR platform. The company highlights dilution and stock overhang risks from warrant exercises and future equity issuances, and notes Nasdaq listing under the symbol CODX.

Rhea-AI Summary

Co-Diagnostics, Inc. filed a registration statement to permit resale by selling stockholders of up to 4,942,341 shares of its common stock, comprised of 54,915 PIPE Shares, 1,592,532 Pre-Funded Warrant Shares and 3,294,894 Common Warrant Shares. The selling holders acquired the securities in a private placement on May 21, 2026. The Company will not receive proceeds from resales, but could receive up to approximately $5.18 million if the Warrants are exercised for cash. Shares outstanding were 3,685,314 as of May 27, 2026. The registration permits the selling stockholders to dispose of shares under various sale methods described in the Plan of Distribution.

Rhea-AI Summary

Co-Diagnostics, Inc. registered a shelf to offer up to $150,000,000 of securities from time to time, including common stock, preferred stock, debt securities, warrants, units and rights.

The prospectus states each offering will be described in a separate prospectus supplement and that net proceeds are intended for working capital and general corporate purposes, with possible uses including product development, sales and marketing expansion, acquisitions and debt repayment.